Effects of interleukin-17 inhibitors on hepatic fibrosis index in patients with psoriasis and metabolic dysfunction-associated fatty liver disease: Directed acyclic graphs
Clinical and Molecular Hepatology. 2022;28(2):269-272 
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
. 2021;
Validation of Fatty Liver Index as a Marker for Metabolic Dysfunction-associated Fatty Liver Disease
. 2021;
Validation of Fatty Liver Index as a Marker for Metabolic Dysfunction-Associated Fatty Liver Disease
. 2021;
Prevalence of Significant and Advanced Hepatic Fibrosis in Metabolic Dysfunction Associated Fatty Liver Disease (MAFLD)
. 2021;
Insulin-related biomarkers and their relationship with hepatic fibrosis risk in patients with psoriasis, metabolic syndrome and non-alcoholic fatty liver disease
Journal of Gastroenterology. 2013;48(5):671-672
A Noninvasive Scoring System for Liver Fibrosis in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease
Gastro Hep Advances. 2022;1(6):1006-1013
Is metabolic‐dysfunction‐associated fatty liver disease or advanced liver fibrosis associated with erythropoietin stimulating agent hypo‐responsiveness among patients with end‐stage kidney disease on haemodialysis?
Nephrology. 2023;
Validation of fatty liver index as a marker for metabolic dysfunction-associated fatty liver disease
Diabetology & Metabolic Syndrome. 2022;14(1):
The Shift from nonalcoholic fatty liver disease to metabolic dysfunction–associated fatty liver disease
Clinical Liver Disease. 2022;20(5):157-161